Enfeksiyon Hastalıklarında Bakteriyofaj Tedavisi
Özet
Bakteriyofaj tedavisi, antibiyotik direncinin küresel bir sağlık sorunu haline gelmesiyle birlikte, bakterileri enfekte ederek yok eden virüslerin kullanımını yeniden gündeme getiren etkili bir alternatiftir. Bu yöntem, özellikle litik yaşam döngüsüne sahip fajların hedef patojeni parçalaması esasına dayanır ve antibiyotiklere dirençli vakalarda yaklaşık %85 oranında başarı sağlamaktadır. Spesifik etki spektrumu sayesinde yararlı florayı koruyan bu tedavi; oral, topikal ve parenteral gibi çeşitli yollarla uygulanabilmekte, biyofilm tabakalarına karşı da etkinlik göstermektedir. Günümüzde gelişen teknolojiyle birlikte diyabetik ayak yaralarından septisemiye kadar geniş bir yelpazede klinik çalışmalarla desteklenerek modernize edilmektedir.
Bacteriophage therapy is an effective alternative that reintroduces the use of viruses to infect and destroy bacteria as antibiotic resistance becomes a global health crisis. This method relies primarily on lytic phages to eradicate target pathogens and achieves approximately an 85% success rate in antibiotic-resistant cases. Due to its specific activity spectrum, it preserves beneficial flora and can be administered through oral, topical, or parenteral routes, showing high efficacy against biofilms. Today, it is being modernized through various clinical studies ranging from diabetic foot infections to septicemia, supported by advancing technologies.
Referanslar
Sulakvelidze A, Alavidze Z, Morris Jr JG. Bacteriophage therapy. Antimicrobial agents and chemotherapy. 2001;45(3):649-59.
Antibiotic / Antimicrobial Resistance (AR / AMR) https://www.cdc.gov/drugresistance/index.html2021 [updated 09/21.
Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, et al. Alternatives to antibiotics–a pipeline portfolio.
Hankin EH. L’action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann Inst Pasteur. 1896;10(11).
Twort FW. An investigation on the nature of ultra-microscopic viruses. Acta Kravsi. 1961.
WC S. Felix d'Herelle and the Origins of Molecular Biology 1999. New Haven, CT Yale University Press.
Fruciano DE, Bourne S. Phage as an antimicrobial agent: d’Herelle’s heretical theories and their role in the decline of phage prophylaxis in the West. Canadian Journal of Infectious Diseases and Medical Microbiology. 2007;18(1):19-26.
Summers WC. Bacteriophage therapy. Annual Reviews in Microbiology. 2001;55(1):437-51.
Himmelweit F. Combined Action of Penicillin and Bacteriophage on Staphylococci. Lancet. 1945:104-5.
Smith HW, Huggins M. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. Microbiology. 1982;128(2):307-18.
Arda M. Bakteriyofajlar (Bakteriyel Viruslar). Temel Mikrobiyoloji Ankara: Medisan Yayınevi; 2011. p. 182-94.
O'Flaherty S, Ross RP, Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS microbiology reviews. 2009;33(4):801-19.
Gill JJ, Hyman P. Phage choice, isolation, and preparation for phage therapy. Current pharmaceutical biotechnology. 2010;11(1):2-14.
Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. Journal of Pharmacy and Pharmacology. 2011;63(10):1253-64.
Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Archivum immunologiae et therapiae experimentalis. 1987;35(5):569-83.
Goodridge LD. Designing phage therapeutics. Current pharmaceutical biotechnology. 2010;11(1):15-27.
Letarov A, Golomidova A, Tarasyan K. Ecological basis for rational phage therapy. Acta Naturae (англоязычная версия). 2010;2(1 (4)).
Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, et al. Long-circulating bacteriophage as antibacterial agents. Proceedings of the National Academy of Sciences. 1996;93(8):3188-92.
Weber-Dąbrowska B, Górski A. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig Med Dosw(online). 2007;61:461-5.
Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011;1(2):66-85.
Letkiewicz S, Międzybrodzki R, Kłak M, Jończyk E, Weber-Dąbrowska B, Górski A. The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunology & Medical Microbiology. 2010;60(2):99-112.
Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, et al. Phage therapy in clinical practice: treatment of human infections. Current pharmaceutical biotechnology. 2010;11(1):69-86.
Markoishvili K, Tsitlanadze G, Katsarava R, Glenn J, Morris Jr M, Sulakvelidze A. A novel sustained‐release matrix based on biodegradable poly (ester amide) s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. International journal of dermatology. 2002;41(7):453-8.
Weber-Dabrowska B, Mulczyk M, Górski A, editors. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplantation proceedings; 2003.
Merabishvili M, De Vos D, Verbeken G, Kropinski AM, Vandenheuvel D, Lavigne R, et al. Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104: H4 strain from the 2011 outbreak in Germany. PLoS One. 2012;7(12):e52709.
Merabishvili M, Vervaet C, Pirnay J-P, De Vos D, Verbeken G, Mast J, et al. Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). PloS one. 2013;8(7):e68797.
Rhoads D, Wolcott R, Kuskowski M, Wolcott B, Ward L, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. Journal of wound care. 2009;18(6):237-43.
Wright A, Hawkins C, Änggård E, Harper D. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic‐resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clinical otolaryngology. 2009;34(4):349-57.
Rose T, Verbeken G, De Vos D, Merabishvili M, Vaneechoutte M, Lavigne R, et al. Experimental phage therapy of burn wound infection: difficult first steps. International journal of burns and trauma. 2014;4(2):66.
Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrobial agents and chemotherapy. 2017;61(10):e00954-17.
Gundogdu A, Bolkvadze D, Kilic H. In vitro effectiveness of commercial bacteriophage cocktails on diverse extended-spectrum beta-lactamase producing Escherichia coli strains. Frontiers in microbiology. 2016;7:1761.
Gündoğdu A, Kılıç H, Ulu Kılıç A, Kutateladze M. Komplike Deri ve Yumuşak Doku Enfeksiyonu Etkeni Çoklu Dirençli Patojenlerin Standart Bakteriyofaj Kokteyllerine Karşı Duyarlılıklarının Araştırılması. Mikrobiyoloji Bülteni. 2016;50(2):215-23.
